Dec 30, 2009:
iCo Therapeutics Grants Options to Directors, Officers and Employees
Dec 11, 2009:
iCo Therapeutics Provides Phase 1 DME Clinical Trial Update and Phase 2 Trial Guidance
Dec 3, 2009:
iCo Therapeutics iCo-007 Overview to be Presented at the 8th International Symposium on Ocular Pharmacology and Therapeutics
Nov 26, 2009:
iCo Therapeutics Q3 2009 Financial Results
Nov 20, 2009:
iCo Therapeutics Completes Final Tranche of $4,000,000 Brokered Private Placement
Oct 30, 2009:
iCo Therapeutics Completes First Tranche of Brokered Private Placement
Oct 20, 2009:
iCo Therapeutics Announces $4,000,000 Brokered Private Placement
Sep 24, 2009:
iCo Therapeutics Signs Collaboration Agreement with The Consortium for Parasitic Drug Development
Aug 21, 2009:
iCo Therapeutics Q2 2009 Financial Results
Jul 21, 2009:
iCo Therapeutics Appoints Infectious Disease MD to Scientific Advisory Board
Jul 16, 2009:
iCo Therapeutics Closes Non-Brokered Private Placement
Jul 7, 2009:
iCo Therapeutics Diabetic Macular Edema Clinical Trial Update
Jul 2, 2009:
iCo Therapeutics Publishes Review of Diabetic Retinopathy Treatment
Jun 25, 2009:
iCo Therapeutics Positive Oral Amphotericin B Data Published in the Journal of Infectious Diseases
Jun 8, 2009:
Shareholders Approve All Resolutions at iCo Therapeutics Annual General Meeting
May 29, 2009:
iCo Therapeutics Q1 2009 Financial Results
Apr 30, 2009:
iCo Therapeutics Year-End 2008 Financial Results
Apr 29, 2009:
iCo Therapeutics to Present at BioFinance 2009
Mar 23, 2009:
iCo Therapeutics Oral Anti-Parasitic Drug to be Presented at Global Health Symposia
Mar 17, 2009:
iCo Therapeutics iCo-007 Second Cohort Results to be Presented at Cleveland Clinic Ocular Conference
Feb 20, 2009:
iCo Therapeutics Grants Options to New Directors
Feb 19, 2009:
iCo Therapeutics iCo-007 Results to be Presented at Prestigious Ocular Conference
Feb 18, 2009:
iCo Therapeutics Oral Amphotericin B Published in Leading Journal
Feb 9, 2009:
iCo Therapeutics Closes $1.3 Million Private Placement
Jan 30, 2009:
iCo Therapeutics Closes First Tranche of Non-Brokered Private Placement